Viatris’s $1.65 Billion Acquisition of Pacira

On October 8, 2026, Viatris Inc. (“Viatris”), a global healthcare company, and Pacira BioSciences, Inc. (“Pacira”), a leader in innovative non‑opioid pain therapies, announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Cravath is representing Viatris in connection with the transaction.

The Cravath team is led by partners Mark I. Greene, Aaron M. Gruber and Andrew M. Wark and includes associates W. Peter Kim, Benjamin Meyer, Reva Bardhi and Hector Reyes on M&A matters; partner J. Leonard Teti II and associates Josh Banafsheha and Andrew Stone on tax matters; partner Jonathan J. Katz, of counsel Sarah W. Colangelo and associate Scarlett A. Neely on executive compensation and benefits matters; partner David J. Kappos, of counsel Carys J. Webb and associate Jason Yung Liang on intellectual property matters; partner Margaret T. Segall and associates Lavinia M. Hecht and Tal Y. Bright on antitrust matters; partner John W. White and of counsel Zachary R. Smith on corporate governance matters; partner Matthew Morreale and of counsel Felise Cooper on environmental matters; and of counsels Joyce Law and Brian M. Budnick on real property matters. Mohamed Camara also worked on antitrust matters.